This Phase III trial is evaluating how well targeted therapy (blinatumomab) works in combination with chemotherapy in treating people with newly diagnosed, standard risk B-lymphoblastic leukaemia or B-lymphoblastic lymphoma..
This trial is treating patients with B Acute Lymphoblastic Leukaemia B Lymphoblastic Lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Other Non-Commercial Sponsor
National Cancer Institute (NCI)
Summary
This is a randomised, open-label trial with multiple active comparator and experimental arms investigating Blinatumomab in combination with chemotherapy in patients with newly diagnosed standard risk or Down Syndrome B-Lymphoblastic Leukaemia (B-ALL) and the treatment of patients with localised B-Lymphoblastic Lymphoma (B-LLy). The trial is seeking to determine whether the addition of 2 cycles of blinatumomab to standard therapy improves disease-free survival.
Recruiting Hospitals Read More